Sort by

Send to

Choose Destination

Links from PubMed

Items: 15


Modeling Melanoma In Vitro and In Vivo.

Beaumont KA, Mohana-Kumaran N, Haass NK.

Healthcare (Basel). 2013 Dec 23;2(1):27-46. doi: 10.3390/healthcare2010027. Review.


Culturing Uveal Melanoma Cells.

Angi M, Versluis M, Kalirai H.

Ocul Oncol Pathol. 2015 Apr;1(3):126-32. doi: 10.1159/000370150. Epub 2015 Apr 9. Review.


Microphthalmia-associated transcription factor in melanoma development and MAP-kinase pathway targeted therapy.

Wellbrock C, Arozarena I.

Pigment Cell Melanoma Res. 2015 Jul;28(4):390-406. doi: 10.1111/pcmr.12370. Epub 2015 Apr 17. Review.


Inhibitor of DNA Binding 4 (ID4) is highly expressed in human melanoma tissues and may function to restrict normal differentiation of melanoma cells.

Peretz Y, Wu H, Patel S, Bellacosa A, Katz RA.

PLoS One. 2015 Feb 2;10(2):e0116839. doi: 10.1371/journal.pone.0116839. eCollection 2015.


MITF in melanoma: mechanisms behind its expression and activity.

Hartman ML, Czyz M.

Cell Mol Life Sci. 2015 Apr;72(7):1249-60. doi: 10.1007/s00018-014-1791-0. Epub 2014 Nov 30. Review.


Identification of a ZEB2-MITF-ZEB1 transcriptional network that controls melanogenesis and melanoma progression.

Denecker G, Vandamme N, Akay O, Koludrovic D, Taminau J, Lemeire K, Gheldof A, De Craene B, Van Gele M, Brochez L, Udupi GM, Rafferty M, Balint B, Gallagher WM, Ghanem G, Huylebroeck D, Haigh J, van den Oord J, Larue L, Davidson I, Marine JC, Berx G.

Cell Death Differ. 2014 Aug;21(8):1250-61. doi: 10.1038/cdd.2014.44. Epub 2014 Apr 25.


Gene expression profiling identifies microphthalmia-associated transcription factor (MITF) and Dickkopf-1 (DKK1) as regulators of microenvironment-driven alterations in melanoma phenotype.

Hartman ML, Talar B, Noman MZ, Gajos-Michniewicz A, Chouaib S, Czyz M.

PLoS One. 2014 Apr 14;9(4):e95157. doi: 10.1371/journal.pone.0095157. eCollection 2014.


From fly wings to targeted cancer therapies: a centennial for notch signaling.

Ntziachristos P, Lim JS, Sage J, Aifantis I.

Cancer Cell. 2014 Mar 17;25(3):318-34. doi: 10.1016/j.ccr.2014.02.018. Review.


Natural compounds' activity against cancer stem-like or fast-cycling melanoma cells.

Sztiller-Sikorska M, Koprowska K, Majchrzak K, Hartman M, Czyz M.

PLoS One. 2014 Mar 3;9(3):e90783. doi: 10.1371/journal.pone.0090783. eCollection 2014.


Octamer-binding transcription factors: genomics and functions.

Zhao FQ.

Front Biosci (Landmark Ed). 2013 Jun 1;18:1051-71. Review.


Parthenolide reduces the frequency of ABCB5-positive cells and clonogenic capacity of melanoma cells from anchorage independent melanospheres.

Czyz M, Koprowska K, Sztiller-Sikorska M.

Cancer Biol Ther. 2013 Feb;14(2):135-45. doi: 10.4161/cbt.22952. Epub 2012 Nov 28.


A phosphatidylinositol 3-kinase-Pax3 axis regulates Brn-2 expression in melanoma.

Bonvin E, Falletta P, Shaw H, Delmas V, Goding CR.

Mol Cell Biol. 2012 Nov;32(22):4674-83. doi: 10.1128/MCB.01067-12. Epub 2012 Sep 17.


Phosphorylation of BRN2 modulates its interaction with the Pax3 promoter to control melanocyte migration and proliferation.

Berlin I, Denat L, Steunou AL, Puig I, Champeval D, Colombo S, Roberts K, Bonvin E, Bourgeois Y, Davidson I, Delmas V, Nieto L, Goding CR, Larue L.

Mol Cell Biol. 2012 Apr;32(7):1237-47. doi: 10.1128/MCB.06257-11. Epub 2012 Jan 30.


Notch signaling promotes growth and invasion in uveal melanoma.

Asnaghi L, Ebrahimi KB, Schreck KC, Bar EE, Coonfield ML, Bell WR, Handa J, Merbs SL, Harbour JW, Eberhart CG.

Clin Cancer Res. 2012 Feb 1;18(3):654-65. doi: 10.1158/1078-0432.CCR-11-1406. Epub 2012 Jan 6.


The novel gamma secretase inhibitor RO4929097 reduces the tumor initiating potential of melanoma.

Huynh C, Poliseno L, Segura MF, Medicherla R, Haimovic A, Menendez S, Shang S, Pavlick A, Shao Y, Darvishian F, Boylan JF, Osman I, Hernando E.

PLoS One. 2011;6(9):e25264. doi: 10.1371/journal.pone.0025264. Epub 2011 Sep 29. Erratum in: PLoS One. 2011;6(11). doi:10.1371/annotation/a89c089f-ae9d-4453-a314-37efd5efb126.

Items per page

Supplemental Content

Write to the Help Desk